🟢 Ultragenyx is trading 5% up today as rebound appears to reflect post-selloff trading

Ultragenyx is trading 5% up at $15.62, rebounding after its September 3, 2026 close of $14.85, when shares fell 44.03%.

• The earlier collapse followed failure of apazunersen to meet the Phase 3 Aspire trial’s primary cognitive endpoint and key secondary MDRI endpoint, with no efficacy difference versus placebo.
• September 4, 2026 coverage provides no new company-specific catalyst for the rebound.